Synthetic sst4 agonists inhibit pain, inflammation (Sándor et al. 2006; Schuelert et al. 2015), depression-like behavior (Scheich et al. 2016), and as neurodegeneration and cognitive dysfunction via increasing neprilysin activity leading to decreased cortical Aβ1–42 formation in rodent models (Sandoval et al. 2011, 2012). This evidence concerns the gene SSTR4 and depressive disorder.